RxDoctor Payments Data

Jones John, DO

Nephrology · Lauderhill, FLNPI 1972814895

Payments from drug & device makers

$803in general payments, 2019–2025

Across 14 payments — averaging $57.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$172
  • Bayer$145
  • Calliditas Therapeutics US Inc.$125
  • Baxter Healthcare$123
  • Vantive US Healthcare LLC$118
  • Novo Nordisk$56
  • plus $64 from 3 others

What the payments were for

  • Food & beverage$77697%
  • Education$273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$803 in reported general payments places this provider in the 30th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$80,199
Medicare patients
149
Services billed
702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol79$67,137
VeltassaPatiromer Calcium Sorbitex21$41,341
JardianceEmpagliflozin35$34,824
KerendiaFinerenone27$22,286
ProsolParenteral Amino Acid 20% No.151$17,300
Calcium Acetate12$1,461
Potassium Chloride27$1,280
Hydralazine Hcl51$609
Losartan Potassium67$430
Pentoxifylline15$412
Nifedipine ErNifedipine19$337
Calcitriol44$323
Valsartan15$320
Carvedilol55$267
Furosemide33$186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$145$22,28627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 756 nephrology providers in Florida.

Other nephrology in Lauderhill

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →